Nanjing Iaso Biotechnology Co., Ltd.
Clinical trials sponsored by Nanjing Iaso Biotechnology Co., Ltd., explained in plain language.
-
New hope for tough lupus cases: experimental therapy UB-VV410 enters human testing
Disease control Recruiting nowThis early-stage study tests an experimental drug called UB-VV410 in 21 adults with active lupus (including lupus nephritis) that hasn't improved with standard treatments. The main goals are to check safety, find the best dose, and see early signs of effectiveness. Participants w…
Phase: PHASE1 • Sponsor: Nanjing IASO Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New gene therapy combo tackles aggressive lymphoma in early trial
Disease control Recruiting nowThis early-stage study is testing a new gene therapy called UB-VV400, alone and with the drug rapamycin, in 70 adults with relapsed or refractory large B-cell lymphoma. The main goals are to find safe doses and check for side effects. Researchers will also look for signs that the…
Phase: PHASE1 • Sponsor: Nanjing IASO Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 17:45 UTC